Teva’s Copaxone Maintains Market Share amid Intense Competition

In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.

Sarah Collins - Author

Nov. 20 2020, Updated 11:57 a.m. ET


Copaxone performance in 1Q18

In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%. In the North America region, Teva registered Copaxone sales of $476 million, representing a YoY (year-over-year) decline of 40% due to increased competition from generics in the United States where the Copaxone sales were $462 million in fiscal 1Q18. In Europe, Copaxone sales registered growth of ~1% to $153 million. However, on a currency adjusted basis, Europe Copaxone sales fell ~13%. In the Growth Market segment, Copaxone sales came in at $16 million, a YoY decline of 24%.

Article continues below advertisement
Article continues below advertisement

Competition from new launches

As per Teva, it has maintained its volume and market share even after the launch of Mylan’s (MYL) 40-milligram dosage of the generic version of Copaxone in October 2017. Pricing has been impacted to a large extent by higher discounts and rebates. The company stated that its 40-milligram US market share has remained at ~85%. However, the company expects to see some more competition from another generic of Copaxone developed by Momenta (MNTA) and Novartis (NVS), which was approved for 40-milligram dosage by the FDA (U.S. Food and Drug Administration) in February 2018.

Teva already has competition from Momenta and Mylan in the 20-milligram market for Copaxone and its generics. Teva expects to see marginal pressure on volumes going forward in 2018. In 2018, Teva expects Copaxone sales to come in at $1.8 billion.

Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!


Latest Novartis AG News and Updates

    Opt-out of personalized ads

    © Copyright 2024 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.